Enwei Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Operating Revenue	884.7	808.19	781.2	687.5	675.79	630.97
Other Revenue	3.94	3.94	3.99	4.07	3.91	3.19
Revenue	888.64	812.13	785.19	691.57	679.7	634.16
Revenue Growth (YoY)	14.57%	3.43%	13.54%	1.75%	7.18%	2.17%
Cost of Revenue	459.07	404.17	384.36	346.2	298.67	271.75
Gross Profit	429.57	407.96	400.83	345.37	381.03	362.41
Selling, General & Admin	358.71	342.52	292.84	258.17	264.71	244.19
Research & Development	7.61	9.07	16.82	7.52	4.32	4.84
Other Operating Expenses	13.38	12.56	10.89	9.89	11.64	10.35
Operating Expenses	379.96	365.98	320.45	277.06	281.34	258.66
Operating Income	49.6	41.98	80.38	68.31	99.69	103.76
Interest Expense	-3.2	-2.43	-	-	-	-0.06
Interest & Investment Income	8.81	7.59	10.3	1.99	0.52	0.33
Other Non Operating Income (Expenses)	3.12	-0.08	-0.66	-0.27	-0.88	-2.16
EBT Excluding Unusual Items	58.34	47.07	90.03	70.03	99.33	101.87
Gain (Loss) on Sale of Investments	-	-	-	-	-0.44	-
Gain (Loss) on Sale of Assets	-0.47	-0.26	-0.04	-	-	0.01
Asset Writedown	4.28	-0.05	-	-	-0.01	-0.08
Other Unusual Items	2.2	-0.06	11.33	11.83	20.25	22.67
Pretax Income	64.35	46.68	101.31	81.86	119.13	124.47
Income Tax Expense	12.29	9.19	15	14.06	17.39	19.29
Earnings From Continuing Operations	52.06	37.5	86.31	67.8	101.73	105.18
Minority Interest in Earnings	-	-	-	-	-	-6.44
Net Income	52.06	37.5	86.31	67.8	101.73	98.74
Net Income to Common	52.06	37.5	86.31	67.8	101.73	98.74
Net Income Growth	47.07%	-56.56%	27.30%	-33.36%	3.03%	19.55%
Shares Outstanding (Basic)	100	101	103	84	78	73
Shares Outstanding (Diluted)	100	101	103	84	78	73
Shares Change (YoY)	-1.90%	-1.82%	21.93%	8.34%	6.51%	-6.12%
EPS (Basic)	0.52	0.37	0.84	0.80	1.31	1.35
EPS (Diluted)	0.52	0.37	0.84	0.80	1.31	1.35
EPS Growth	49.92%	-55.75%	4.40%	-38.49%	-3.27%	27.35%
Free Cash Flow	32.89	28.69	-50.04	38.8	49.36	47.36
Free Cash Flow Per Share	0.33	0.28	-0.49	0.46	0.63	0.65
Dividend Per Share	0.530	0.180	0.540	1.600	-	0.875
Dividend Growth	-1.94%	-66.70%	-66.22%	-	-	53.33%
Gross Margin	48.34%	50.23%	51.05%	49.94%	56.06%	57.15%
Operating Margin	5.58%	5.17%	10.24%	9.88%	14.67%	16.36%
Profit Margin	5.86%	4.62%	10.99%	9.80%	14.97%	15.57%
Free Cash Flow Margin	3.70%	3.53%	-6.37%	5.61%	7.26%	7.47%
EBITDA	102.06	86.85	115.13	99.22	127.79	136.54
EBITDA Margin	11.48%	10.69%	14.66%	14.35%	18.80%	21.53%
D&A For EBITDA	52.46	44.87	34.75	30.91	28.1	32.79
EBIT	49.6	41.98	80.38	68.31	99.69	103.76
EBIT Margin	5.58%	5.17%	10.24%	9.88%	14.67%	16.36%
Effective Tax Rate	19.10%	19.68%	14.81%	17.18%	14.60%	15.50%
Revenue as Reported	888.64	812.13	785.19	691.57	679.7	634.16
Advertising Expenses	-	96.67	69.92	44.22	-	30.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.